Short Interest in Cel-Sci Corporation (NYSEAMERICAN:CVM) Declines By 40.5%

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 714,471 shares, a decrease of 40.5% from the July 30th total of 1,200,354 shares. Approximately 4.8% of the company’s stock are short sold. Based on an average daily trading volume, of 271,896 shares, the days-to-cover ratio is presently 2.6 days.

Cel-Sci Stock Down 0.6%

NYSEAMERICAN CVM traded down $0.01 during trading hours on Tuesday, reaching $1.61. 70,028 shares of the company’s stock traded hands, compared to its average volume of 261,749. Cel-Sci has a 52-week low of $0.89 and a 52-week high of $12.68. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.48 and a quick ratio of 1.42. The firm has a 50-day simple moving average of $1.32 and a 200 day simple moving average of $2.38. The firm has a market cap of $28.14 million, a PE ratio of -0.16 and a beta of 0.63.

Cel-Sci (NYSEAMERICAN:CVM) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.47) earnings per share for the quarter.

Institutional Trading of Cel-Sci

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Cel-Sci by 59.7% during the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after buying an additional 109,352 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Cel-Sci by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock worth $417,000 after acquiring an additional 18,432 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after acquiring an additional 39,190 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Cel-Sci by 133.0% in the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock worth $115,000 after acquiring an additional 20,484 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Cel-Sci by 9.9% during the fourth quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after acquiring an additional 2,300 shares in the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.